CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial - RATIONAL-PT
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Phase 2 Trial of ASTX727 and Venetoclax Compared with ASTX727, Venetoclax, and Enasidenib for Newly Diagnosed Older Adults with IDH2 Mutant AML - A myeloMATCH Substudy
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
CCTG is pleased to announce that the 2026 Annual Spring Meeting of Participants will be held April 24-26, 2026, at the Chelsea Hotel in Toronto.
In recent years, immunotherapies have emerged as a promising class of cancer drugs that harnesses the power of the immune system to fight cancer. But despite their life-saving potential, their effectiveness is limited: only 20 to 30 per cent of people with cancer benefit from them and some experience severe side effects without any therapeutic benefit.
Immunotherapy is an innovative type of cancer treatment that harnesses the patient's own immune system to recognize and eliminate cancer cells. In the last decade, the use of immunotherapy has increased exponentially, and it is now applied as the treatment of choice in many different cancer types. This popularity comes from the remarkable results seen in some patients treated with immunotherapy, which can lead to a cure in some cases and significantly prolong patient lives in others.
The CCTG Patient Representative Committee is pleased to welcome Deb Clark who will support the Gynecologic Disease site committee. Deb lives in Regina and her journey began when her mom was diagnosed with ovarian cancer, now a 26-year cancer survivor. Deb supported her mom as her caregiver through three additional, primary cancers and was her husband’s caregiver when he had oral cancer.
